NCT05201287 is a NA clinical trial of VIA Disc NP in Degenerative Disc Disease, sponsored by VIVEX Biologics, Inc..

Who is sponsoring NCT05201287?

NCT05201287 is sponsored by VIVEX Biologics, Inc..

What drugs are being tested in NCT05201287?

Interventions in NCT05201287: VIA Disc NP.

What condition does NCT05201287 study?

NCT05201287 studies Degenerative Disc Disease, Low Back Pain, Disc Degeneration.

Is NCT05201287 still recruiting?

NCT05201287 is currently active, enrolled. Last updated 29 April 2024.

Last reviewed 2024-04-29 · How we verify

NCT05201287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

Active, enrolled NA Last updated 29 April 2024

What this trial tests

NA trial testing VIA Disc NP in Degenerative Disc Disease in 35 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

30 December 2021

Primary endpoint
5 January 2023

27 December 2024

Quick facts

Lead sponsor	VIVEX Biologics, Inc.
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	30 December 2021
Primary completion	5 January 2023
Estimated completion	27 December 2024
Sites	6 locations across United States

Drugs / interventions tested

VIA Disc NP

Conditions studied

Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
Low Back Pain — all drugs for Low Back Pain →
Disc Degeneration — all drugs for Disc Degeneration →

Sponsor

VIVEX Biologics, Inc. — full company profile →

Who can join

18 and older, any sex, with Degenerative Disc Disease or Low Back Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

VIA Disc NP is an allograft intended to supplement the nucleus pulposus tissue in degenerated intervertebral discs.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Durability of Supplemental Nucleus Pulposus Allograft in Patients with Lumbar Discogenic Pain.
Costandi S, Beall DP, Davis TT, Amirdelfan K, et al · · 2025 · cited 2× · PMID 40226828 · DOI 10.2147/jpr.s516571
Supplemental nucleus pulposus allograft in patients with lumbar discogenic pain: results of a prospective feasibility study.
Beall DP, Davis TT, Amirdelfan K, Naidu RK, et al · · 2025 · cited 1× · PMID 40312677 · DOI 10.1186/s12891-025-08701-0

Verify or expand the search:

Other trials of VIA Disc NP

Trials testing the same drug.

NCT06345690 — VIA Disc NP Registry 3.0 · recruiting

Other recruiting trials for Degenerative Disc Disease

Currently open trials in the same condition.

NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
NCT06704919 — Conduit Cages and Fibergraft BG Putty · recruiting
NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting

Other VIVEX Biologics, Inc. trials

Trials by the same sponsor.

NCT06345690 — VIA Disc NP Registry 3.0 · recruiting
NCT05412277 — VIA Disc Nucleus Pulposus Older Patients Pilot · NA · active not recruiting
NCT05196191 — Wound Healing Following Penile Prosthesis Implant · NA · terminated
NCT04835389 — Study of AlloGen® Liquid Intra-articular Injection for Knee Osteoarthritis · Phase 1 · withdrawn
NCT04652687 — VIA Disc NP Registry · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05201287 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VIVEX Biologics, Inc.
Last refreshed: 29 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05201287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing